AVEO receives EMA orphan medicinal product designation for tivozanib AVEO Pharmaceuticals.

, a biopharmaceutical company focused on discovering, commercializing and developing cancer therapeutics, today announced it has received orphan medicinal product designation for tivozanib oxy]phenyl-N’- urea hydrochloride monohydrate), its oral, triple VEGF receptor inhibitor, for the treatment of renal cell carcinoma by the European Medicines Agency . According to the EMA, tivozanib was awarded orphan medicinal product designation based on the prevalence of renal cell carcinoma among people in the European Union ; the life-threatening nature of the disease particularly for those with advanced or metastatic renal cell carcinoma; and the assumption that tivozanib may provide significant benefit for patients with renal cell carcinoma, and may be more potent and specific than existing treatments with similar mechanism of action as supported by preliminary clinical results.Johns Hopkins co-senior research investigator and infectious disease professional Robert Siliciano, M.D., Ph.D., says the mathematical model could also be used to predict how well an individual will probably do on a specific regimen, predicated on their prescription adherence. In addition, the model elements in each drug’s capability to suppress viral replication and the chance that such suppression will spur development of drug-resistant, mutant HIV strains. Related StoriesNew vaccine candidate shows great promise at fighting respiratory syncytial virusGenvoya accepted as complete regimen for HIV treatmentDengue-infected sufferers with few or no symptoms transmit virus to mosquitoes’By using our simulation, we can today tell with a fair amount of certainty what level of viral suppression has been achieved – how hard it really is for the virus to develop and replicate – for a particular drug combination, at a specific drug and dosage focus in the blood, when a dose is missed even,’ says Siliciano, a professor at the Johns Hopkins University College of Medication and a Howard Hughes Medical Institute investigator.